(Q42852277)

8 November 2017

title

Therapy: What evidence should guide the use of thiazolidinediones? (English)

1 reference

8 November 2017

Matthew C Riddle

1

1 reference

8 November 2017

publication date

1 November 2010

1 reference

Nature Reviews Endocrinology

8 November 2017

published in

1 reference

8 November 2017

volume

6

1 reference

8 November 2017

issue

11

1 reference

8 November 2017

page(s)

600-602

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.156

8 November 2017

exact match

0 references

cites work

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Thiazolidinediones and Heart Failure: A teleo-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

A randomized trial of therapies for type 2 diabetes and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.156

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2010.156

1 reference

8 November 2017

1 reference